类风湿关节炎治疗新进展:生物制剂与小分子药物发展概览及未满足需求
综述概述了生物制剂DMARDs和靶向合成DMARDs(如JAK抑制剂)联合甲氨蝶呤使临床缓解成为多数RA患者的现实治疗目标,长期安全性和持续抑制结构损伤已有报告,五种JAK抑制剂疗效与生物制剂DMARDs相当,最新品种对难治性RA有效,但JAK抑制剂治疗需充分筛查和监测感染、心血管病、血栓、恶性肿瘤等,治疗策略进展包括药物差异化使用和缓解后降阶治疗。
要点
- 生物制剂DMARDs或靶向合成DMARDs联合甲氨蝶呤使临床缓解成为多数RA患者的现实目标。
- 五种JAK抑制剂疗效与生物制剂DMARDs相当,最新品种对难治性RA有效。
- JAK抑制剂治疗应充分筛查和监测感染、心血管病、血栓、恶性肿瘤等。
核心结论
- 生物制剂DMARDs或靶向合成DMARDs(如JAK抑制剂)联合甲氨蝶呤使临床缓解成为多数RA患者的现实治疗目标,持续缓解有助于预防关节损伤和躯体功能障碍。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 长期安全性和生物制剂DMARDs持续抑制结构改变和躯体功能障碍已有报告。
- 五种JAK抑制剂显示出与生物制剂DMARDs相当的疗效,最新品种无论既往用药如何均对难治性RA有效。
临床怎么用
- JAK抑制剂治疗患者应充分筛查和监测感染、心血管疾病、血栓、恶性肿瘤等。
- 治疗策略进展优先考虑药物差异化使用和缓解诱导后降阶治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs) such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a realistic therapeutic goal for the majority of patients with RA, and sustained remission facilitates prevention of joint damage and physical dysfunction. Long-term safety and sustained inhibition of structural changes and physical dysfunction by bDMARDs have been reported. The development of next-generation bDMARDs and expansion of their indications to various autoimmune diseases are expected. Five JAK inhibitors show comparable efficacy to bDMARDs, and the latest ones are effective for overcoming difficult-to-treat RA regardless of prior medications. Patients treated with JAK inhibitors should be adequately screened and monitored for infection, cardiovascular disorders, thrombosis, malignancies and so on. Advances in therapeutic strategies, including the differential use of therapeutic drugs and de-escalation of treatment after remission induction, are prioritized.
引用
- Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford). 2021. PMID: 34951925. doi:10.1093/rheumatology/keab609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。